Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology

This article was originally published in Start Up

Executive Summary

The lesson that entrepreneurs and VCs seem to be taking from the fast-paced ophthalmology sector is the need for shorter development time frames and clinical candidates with reduced risk. Among others, MacuSight, Danube, and Lux, profiled here, are to one extent or another revisiting the existing pharmacopeia to test ophthalmic indications for existing compounds.
Advertisement

Related Content

The Eyes Still Have It: Finding Cures For Diseases that Blind Remains Top Focus for Investors, Entrepreneurs
Start-Up News March 2007
In Brief February 2007
MacuSight Inc.
An Early Peek at Glaucoma Devices
From The Foundry, an Incubator Focused on Ophthalmology
Spotting Switching Opportunities in Ophthalmology
OSI Buys Eyetech, Market Rubs Eyes
Devices for Age-Related Macular Degeneration
IPO Step-Ups By Therapeutic Area: Is Your Disease Focus Hot or Not?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091290

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel